Defunct Company
Total Trials
14
As Lead Sponsor
13
As Collaborator
1
Total Enrollment
590
NCT01896180
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
Phase: Phase 2
Role: Lead Sponsor
Start: Jul 31, 2013
Completion: Jan 31, 2014
NCT02289755
Evaluating ALLN-177 for Reducing Urinary Oxalate Excretion in Calcium Oxalate Kidney Stone Formers With Hyperoxaluria
Start: Sep 30, 2014
Completion: Feb 28, 2015
NCT02503345
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Hyperoxaluria and Kidney Stones
Start: Jul 31, 2015
Completion: Jan 31, 2017
NCT02547805
Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days
Start: Sep 30, 2015
NCT03095885
A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria
Phase: N/A
Start: Nov 30, 2016
Completion: Mar 31, 2017
NCT03456830
Evaluate ALLN-177 in Patients With Enteric Hyperoxaluria
Phase: Phase 3
Start: May 21, 2018
Completion: Oct 28, 2019
NCT03391804
Study of ALLN-177 in Patients Aged 12 Years or Older With Enteric or Primary Hyperoxaluria and Hyperoxalemia
Start: Jul 17, 2018
Completion: Dec 13, 2019
NCT03847090
Establishing the Safety and Efficacy of Reloxaliase in Patients With Enteric Hyperoxaluria
Start: Aug 26, 2019
Completion: May 19, 2022
NCT04236219
ALLN-346 Single Ascending Dose (SAD) Study in Healthy Volunteers
Phase: Phase 1
Start: Sep 2, 2020
Completion: Nov 6, 2020
NCT04829435
Study 102: Multiple Ascending Dose Study of ALLN-346 (Engineered Urate Oxidase)
Start: Apr 21, 2021
Completion: Jun 1, 2021
NCT04987242
An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)
Start: Jul 16, 2021
Completion: Mar 2, 2022
NCT05168683
Scintigraphy Study in Healthy Volunteers to Characterize the Performance of ALLN-346 Tablets
Start: Jan 11, 2022
Completion: Feb 23, 2022
NCT04987294
Phase IIa Study of ALLN-346 (Engineered Urate Oxidase) in Subjects With Hyperuricemia, Gout and Chronic Kidney Disease
Start: Sep 2, 2022
Completion: Sep 2, 2022
NCT05657041
Body Weight Adjusted Clopidogrel Treatment in Patients With CORonary Artery Disease
Phase: Phase 2/3
Role: Collaborator
Start: Apr 26, 2023
Completion: Nov 1, 2024